The Latest Breaking News from Leukemia

The manager's eight-year-old son Josh was diagnosed with leukemia in June but is making good progress

Seeking to help researchers find a new treatment approach for children fighting cancer recurrence, cannabis industry pioneer Joe Caltabiano, co-founder of Cresco Labs (OTC: CRLBF) and founder of JSC Fund, a family office seeking opportunities in regulated markets including cannabis, has made a $250,000 donation to

Before the game, he sent a video message to the five-year-old.

The deadliest cancers aren't necessarily the ones that kill the most people overall; they're the ones with the lowest survival rates.

Ramee was successful at balancing the scales between his profession and his home life.

Most common forms of the disease were leukemia and those affecting the central nervous system.

He was diagnosed with chronic lymphocytic leukemia in 2014 and shared in April that he needed to undergo a bone marrow transplant.

Amgen (NASDAQ:AMGN) announced top-line results from the global Phase 3 CodeBreaK 200 trial evaluating once daily oral LUMAKRAS (sotorasib) in patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC), the study met primary endpoint. Amgen shares traded in a range of $238.29 to $240.31 on day volume of 2.43 million shares, closed regular…

The Italian dad and Japanese mom of a two-year-old with a rare kind of leukemia have launched a crowdfunding campaign to find a special donor matching their child’s genetic makeup.

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D). Insulet shares traded in a range of $260.13 to $266.73 on day volume of 200.86 thousand shares…